Newborn Screening and Early Treatment for Rare Genetic Disorder
(Ivanhoe Newswire) ““ Researchers believe that newborn screening and early treatment for a rare genetic disorder, mucopolysaccharidosis type I (MPS I), is needed so that enzyme replacement therapy can begin at birth and eliminate all the symptoms associated with MPS I.
MPS I is an inherited genetic disorder that affects many body systems. It is caused by a defect in the gene that makes an enzyme called alpha-L-iduronidase. Because of this defect, cells either produce the enzyme in low amounts or cannot produce it at all. The enzyme is needed to break down substances called “glycosaminoglycans,” which are by-products of chemical reactions in the body’s cells. If glycosaminoglycans are not broken down, they build up in the cell, eventually leading to cell, tissue and organ damage.
The study is the first to show that early treatment with enzyme replacement therapy for MPS I can significantly decrease symptoms in the heart, bones, and brain. The researchers also found that treating at a higher dose at birth significantly improved the response to enzyme replacement therapy, and that direct treatment into the spinal fluid resulted in a major improvement in brain pathology.
“People with MPS I currently suffer from disease in the heart, bones, and brain, despite state-of-the-art care. Our research shows that with early intervention, these problems can be almost completely prevented,” Patricia Dickson, MD, a LA BioMed principal investigator and co-author of the study, was quoted as saying. “We found that treatment from birth with enzyme replacement therapy significantly improved outcomes, a finding that should be a huge boost to efforts to include MPS I in the diagnostic screening already performed on every newborn in the U.S.”
Currently, there is no cure for these disorders, but enzyme replacement therapy is able to give the missing enzyme back to the patient through an injection. In this study, the use of the alpha-L-iduronidase enzyme at birth in animal models with MPS I prevented nearly every aspect of MPS I disease, including in the brain. Previous studies performed on older patients were only able to incompletely reduce MPS I symptoms with enzyme replacement therapy.
The early treatment prevented the build-up of lysosomal substances in the liver, spleen, lungs, kidneys and heart, suggesting that enzyme replacement therapy could potentially eliminate the symptoms of MPS I in babies before the symptoms start.
“Most of our patients are diagnosed with MPS I only after they begin to manifest symptoms, so enzyme replacement therapy begins after they’ve already suffered damage from the disorder,” said Dr. Dickson. “A test for identifying children with MPS I at birth already exists, and it will soon be possible to add the test to the newborn screening performed in hospitals around the country to identify other genetic disorders. While MPS I in itself is rare, our study implies that early treatment may have substantial benefit for the class of problems called lysosomal storage disorders, which ““ taken together ““ occur in one out of every 5,000 babies born in the U.S.”
SOURCE: Science Translational Medicine, published online December 28, 2010